Psychedelic Therapeutics Market By Product Type (Ketamine and Esketamine, Psilocybin, MDMA, LSD, DMT and 5-MeO-DMT, Other Psychedelic Compounds); By Application (Treatment-Resistant Depression, Major Depressive Disorder, Post-Traumatic Stress Disorder, Anxiety Disorders, Substance Use Disorders, Other Psychiatric Disorders); By End User (Specialty Psychiatry Clinics, Hospitals, Authorised Psychedelic Treatment Centres, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Psychedelic Therapeutics Market: Phase 3 Progress, Supervised-Care Economics and the Race to Commercial Approval

The Global Psychedelic Therapeutics Market was valued at USD 2.60 billion in 2025 and is projected to reach USD 7.75 billion by 2032, expanding at a CAGR of 16.9% during 2026–2032, according to Strategic Market Research.

 

The psychedelic therapeutics landscape is still at an early stage, with ketamine (Ketalar) and esketamine (Spravato) currently representing the only FDA-approved psychedelic-related treatments. Both agents are classified as dissociatives rather than classic psychedelics. The emerging R&D pipeline is increasingly focused on classic psychedelic compounds, particularly psilocybin and other serotonin receptor agonists. These therapies are being investigated for difficult-to-treat psychiatric conditions, including treatment-resistant depression and post-traumatic stress disorder. Growing clinical evidence and investment are expected to accelerate innovation and expand future treatment options in this field.

 

Supervised Treatment Changes the Revenue Model

Psychedelic therapeutics are drug-driven, but their commercial unit is the treated patient and supervised administration session rather than the prescription alone. Most leading candidates are designed for use in specialist psychiatric clinics, hospitals or authorised treatment centres where patient screening, dosing, observation and follow-up are delivered through one controlled pathway.

Spravato provides the clearest commercial benchmark. Johnson & Johnson reported worldwide sales of USD 1.696 billion in 2025, including USD 1.485 billion in the US. Using the SMR market baseline, Spravato revenue was equivalent to approximately 65.2% of the 2025 market value, while the US contributed 87.6% of the brand’s worldwide revenue. Global sales reached USD 1.052 billion in the first half of 2026, increasing by 43.2% year over year. The figures demonstrate that a supervised psychiatric medicine can achieve substantial scale when specialist adoption, payer coverage and treatment-site capacity align.

Classic psychedelic candidates may create a less recurring revenue pattern. Several advanced programmes use one or two administrations rather than ongoing maintenance dosing. Manufacturers may therefore depend on higher treatment-course value, durable outcomes and follow-up services instead of repeated prescription volume.

 

Depression Creates the Strongest Patient and Pipeline Base

Depression-related indications currently provide the strongest near-term demand base. The 2025 National Survey on Drug Use and Health estimated that 19.7 million US adults, or 7.4% of the adult population, experienced a major depressive episode during the previous year. A peer-reviewed claims-based analysis estimated that 8.9 million adults were receiving medication for major depressive disorder and that 2.8 million, or 30.9%, had treatment-resistant depression.

The treatment-resistant population is commercially more relevant than total depression prevalence because leading candidates are being developed for people who have already failed conventional treatment. Patient conversion will depend on product-specific eligibility, prior treatment history, specialist referral, payer authorisation and access to a qualified clinic. The addressable market will therefore be smaller than the broad disease pool.

PTSD adds a separate development pathway. The US Department of Veterans Affairs estimated that about 5% of adults experienced PTSD in a given year, equal to approximately 13 million people in 2020. This burden supports the development of MDMA, methylone and related compounds, although regulatory requirements and the need for psychological support create a more complex commercial pathway than conventional prescription medicines.

 

Psilocybin Holds the Most Advanced Classic-Psychedelic Position

Psilocybin has gained the strongest late-stage position within the classic-psychedelic segment, led by Compass Pathways’ COMP360 programme for treatment-resistant depression. The first pivotal Phase 3 study, COMP005, included 258 participants across 32 US sites. Compass reported that a single 25 mg dose produced a 3.6-point placebo-adjusted improvement on the Montgomery–Åsberg Depression Rating Scale at six weeks, with a p-value below 0.001.

The second pivotal study, COMP006, also met its primary endpoint. Compass reported a 3.8-point difference between two 25 mg administrations and the 1 mg comparison group, again with a p-value below 0.001. Two successful pivotal read-outs place COMP360 ahead of other classic psychedelic candidates in regulatory maturity and provide the strongest current basis for a possible US filing.

Regulatory activity also favours psilocybin. In April 2026, the FDA issued three national priority vouchers for psychedelic-related psychiatric programmes: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder and methylone for PTSD. Psilocybin therefore represented two-thirds of the priority-voucher mix. The FDA also allowed the first US early-stage study of a noribogaine derivative for alcohol use disorder to proceed.

In July 2026, the FDA finalised dedicated guidance for clinical investigations of psychedelic drugs. The guidance addresses trial conduct, data generation, patient monitoring, manufacturing quality and the difficulty of producing reliable results when participants may recognise that they received an active psychoactive compound. This gives developers clearer regulatory expectations while raising the evidence standard for products seeking approval.

 

Shorter Sessions and Broader Indications Reshape Pipeline Value

Competition is moving beyond psilocybin towards candidates differentiated by treatment duration, indication breadth and compatibility with existing antidepressants. Eli Lilly’s July 2026 agreement to acquire AtaiBeckley valued the company at approximately USD 2.8 billion upfront, with up to USD 1.0 billion in additional contingent value tied to development, approval and US rescheduling milestones. The transaction brings large-pharma resources into a pipeline containing BPL-003, VLS-01 and EMP-01.

BPL-003 is an intranasal 5-MeO-DMT formulation being developed for treatment-resistant depression and has initiated Phase 3 activities. VLS-01 is a buccal DMT formulation in Phase 2 development, while EMP-01 is an R-MDMA candidate for social anxiety disorder. The strategic interest in these assets reflects the commercial importance of rapid administration and durable benefit, especially where shorter clinic occupancy can improve treatment-room turnover.

Helus is developing CYB003, a deuterated psilocin analogue, as an adjunctive treatment for major depressive disorder. Its Phase 3 PARADIGM programme combines two pivotal studies with planned enrolment of approximately 550 participants. The EMBRACE study alone is designed for 330 patients at around 60 sites across the US, Europe and Australia. Participants remain on stable antidepressant therapy, which could reduce the disruption associated with medication washout and broaden future adoption.

Definium Therapeutics is developing MM120, a pharmaceutical LSD formulation, for generalised anxiety disorder. Its Panorama Phase 3 study is expected to enrol approximately 250 participants across the US and Europe, with a 12-week controlled period followed by a 40-week extension. The programme expands commercial opportunity beyond depression and PTSD, although LSD’s longer psychoactive duration places greater importance on clinical durability and treatment-site economics.

 

Australia Demonstrates Access but Not Yet Scale

Australia provides the clearest direct evidence of regulated therapeutic use involving MDMA and psilocybin. Under the Therapeutic Goods Administration’s Authorised Prescriber pathway, specialist psychiatrists can prescribe MDMA for PTSD and psilocybin for treatment-resistant depression within controlled treatment protocols.

As of 16 September 2025, the TGA reported 30 authorised MDMA prescribers and 26 authorised psilocybin prescribers. Since the programme began in July 2023, providers had reported 87 MDMA-treated patients and 47 psilocybin-treated patients. MDMA represented 64.9% of reported utilisation, compared with 35.1% for psilocybin.

The combined 134 reported patients across 56 substance-specific prescriber authorisations equal fewer than 2.5 patients per authorisation. This low initial ratio illustrates how provider capacity, ethics approval and patient affordability can restrict volume even after legal access begins.

The Australian pathway is mainly privately funded because MDMA and psilocybin products used through the scheme are not eligible for listing on the Pharmaceutical Benefits Scheme. Treatment costs must be paid by the patient or a third party. This supports a premium private-care segment but limits adoption among patients unable to fund both the medicine and the professional-care package.

 

Regional Expansion Will Follow Different Commercial Routes

North America is the principal near-term market because the US combines the largest established supervised-treatment revenue base with advanced clinical programmes and active FDA support. The region is also the centre of commercial preparation for COMP360, short-duration tryptamines and next-generation psilocin candidates.

Europe is becoming an important clinical-development and future launch region rather than a single uniform market. Compass enrolled 581 participants across North America and Europe in COMP006, with 296 participants receiving 25 mg, 142 receiving 10 mg and 143 receiving 1 mg. This multinational footprint provides treatment-site experience beyond the US and prepares investigators for possible commercial delivery.

The CYB003 and MM120 programmes are also using European sites, while EMBRACE includes Australia alongside the US and Europe. These trials are building a wider base of trained investigators and specialist centres, but commercial access will remain country-specific because pricing, reimbursement and controlled-substance requirements differ across national healthcare systems.

Asia-Pacific’s current medical-access leadership comes from Australia. Its controlled-prescribing framework provides an early commercial model, while inclusion in multinational late-stage studies gives the region additional infrastructure for future product launches.

 

Competition Is Shifting Towards Launch Execution

The market now contains three competitive groups: an established interventional-psychiatry leader, late-stage psychedelic specialists and large pharmaceutical companies entering through acquisitions or partnerships.

Johnson & Johnson holds the strongest approved commercial position through Spravato and its relationships with clinics, specialty distributors and payers. Compass leads the classic psilocybin segment through two successful Phase 3 studies. Lilly’s proposed acquisition of AtaiBeckley increases competitive pressure in DMT and 5-MeO-DMT development, while Helus and Definium are expanding the addressable opportunity into broader depression and anxiety populations.

Lykos Therapeutics’ unsuccessful 2024 MDMA application remains an important competitive lesson. The FDA’s Complete Response Letter identified deficiencies that prevented the product from being legally marketed and required a complete resubmission before another review cycle could begin. The programme increased industry attention on trial design, safety-data quality, durability and the separation of drug effects from accompanying psychological support.

 

Clinic Capacity Will Determine Final Revenue Conversion

The psychedelic therapeutics market has moved closer to commercial maturity through successful pivotal studies, formal FDA guidance, priority-review actions and major pharmaceutical investment. The remaining challenge is converting clinical interest into practical treatment capacity.

Every approved product will require trained specialists, suitable treatment rooms, monitoring staff, secure product handling and payer authorisation. These requirements create a longer and more complex revenue pathway than ordinary antidepressant prescribing.

The strongest products are likely to combine durable clinical outcomes with manageable administration time, predictable retreatment requirements and reimbursement that covers both medicine and supervised care. Short-duration products may increase patient throughput, while longer-duration treatments will need sufficient outcome value to support higher service costs.

 

Psychedelic Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.60 Billion
Revenue Forecast in 2032	USD 7.75 Billion
Overall Growth Rate	CAGR of 16.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Ketamine and Esketamine, Psilocybin, MDMA, LSD, DMT and 5-MeO-DMT, Other Psychedelic Compounds
By Application	Treatment-Resistant Depression, Major Depressive Disorder, Post-Traumatic Stress Disorder, Anxiety Disorders, Substance Use Disorders, Other Psychiatric Disorders
By End User	Specialty Psychiatry Clinics, Hospitals, Authorised Psychedelic Treatment Centres, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of treatment-resistant mental health disorders, increasing clinical research activity around psychedelic-based therapies, growing regulatory interest in novel psychiatric treatments, and expansion of specialised psychedelic treatment infrastructure
Customization Option	Available upon request